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Abstract
It is valuable to establish a population‐based prevaccination baseline distribution of 
human papillomavirus (HPV) types among women with high‐grade cervical intraepi-
thelial neoplasia (CIN) grade 2 or 3 and cervical cancer in order to assess the poten-
tial impact of HPV vaccination. In four countries (Denmark, Norway, Sweden, and 
Iceland), we collected consecutive series of cervical cancers (n = 639) and high‐
grade precancerous cervical lesions (n = 1240) during 2004‐2006 before implemen-
tation of HPV vaccination and subjected the specimens to standardized HPV 
genotyping. The HPV prevalence was 82.7% (95% confidence interval [CI] 79.0‐86.4) 
in CIN2, 91.6% (95% CI 89.7‐93.5) in CIN3, and 86.4% (95% CI 83.7‐89.1) in cervi-
cal cancer. The most common HPV types in CIN2/3 were HPV16 (CIN2: 35.9%, 
95% CI 31.2‐40.6; CIN3: 50.2%, 95% CI 46.8‐53.6) and HPV31 (CIN2: 10.9%, 95% 
CI 7.8‐13.9; CIN3: 12.1%, 95% CI 9.9‐14.3), while HPV16 and HPV18 were the 
most frequent types in cervical cancer (48.8%, 95% CI 44.9‐52.7 and 15.3%, 95% CI 
12.5‐18.1, respectively). The prevalence of HPV16/18 decreased with increasing age 
at diagnosis in both CIN2/3 and cervical cancer (P < 0.0001). Elimination of 
HPV16/18 by vaccination is predicted to prevent 42% (95% CI 37.0‐46.7) of CIN2, 
57% (95% CI 53.8‐60.5) of CIN3 and 64% (95% CI 60.3‐67.7) of cervical cancer. 
Prevention of the five additional HPV types HPV31/33/45/52/58 would increase the 
protection to 68% (95% CI 63.0‐72.2) in CIN2, 85% (95% CI 82.4‐87.2) in CIN3 and 
80% (95% CI 77.0‐83.2) in cervical cancer. This study provides large‐scale and rep-
resentative baselines for assessing and evaluating the population‐based preventive 
impact of HPV vaccination.
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1 |  INTRODUCTION
Globally, more than 500 000 women are diagnosed every year 
with cervical cancer, and around 260 000 women die, mak-
ing it the fourth most common cancer in women.1 Normal 
cervical epithelium may develop through high‐grade cervical 
intraepithelial neoplastic (CIN) lesions into cervical cancer. 
This transition requires persistent infection with oncogenic 
types of human papillomavirus (HPV),2 of which HPV16 
and 18 have the greatest oncogenic potential.3,4 Together, 
HPV16/18 causes approximately 70% of cervical cancer.3,4
Since licensure of the first HPV vaccine in 2006, the four 
countries in this study have implemented HPV vaccination in 
their national immunization programs. Denmark and Norway 
initiated HPV vaccination in 2009, followed by Iceland (2011) 
and Sweden (2012), with all HPV vaccination programs tar-
geting 10‐12 years old girls. In Denmark, a catch‐up program 
aimed at girls aged 13‐15 years was included from 2009 and 
was in 2012 expanded to women up to 27 years of age. In 
Sweden, girls aged 13‐17 years had access to subsidized 
HPV vaccination during 2007‐2011, while the national vac-
cination program in 2012 included a catch‐up program with 
free vaccination of girls aged 13‐18 years.6 The vaccines used 
in the programs targeted either four (16/18 and 6/11) or two 
(16/18) HPV types. A recently launched HPV vaccine targets 
five additional oncogenic HPV types (31/33/45/52/58). The 
generally high participation rates (50%‐90%) in both HPV 
vaccination programs and cervical screening programs in the 
Nordic female populations,6 as well as the comprehensive 
registries and biobanking systems, make these countries an 
ideal setting for studying the population‐based preventive ef-
fects of HPV vaccines. The vaccination programs in Denmark 
and Sweden have been shown to reduce the incidence of geni-
tal warts (90% of which are caused by HPV6/11) and cervical 
precancerous lesions.7,8 It will take longer before a decrease 
in the occurrence of cervical cancer can be observed. We 
wished to establish a Nordic baseline distribution (ie, prior 
to the vaccine initiation) of HPV types in cervical cancer and 
high‐grade cervical lesions as a basis for assessment and fu-
ture evaluation of the population‐preventive impact of HPV 
vaccination and potential HPV type replacement. Previous 
studies have reported a higher prevalence of HPV16/18 with 
increasing severity of cervical lesions.10,11 However, only 
few studies have examined the age‐specific distribution of 
HPV types among population‐based series of women with 
either cervical cancer or high‐grade precancerous cervical 
lesions.4,13,14
The aim of this study was to assess the prevalence and age‐
specific distribution of HPV types in different grades of severe 
CIN (grades 2 and 3) and cervical cancer among women from 
Denmark, Iceland, Norway, and Sweden, during 2004‐2006. 
This will enable establishment of a baseline for surveillance 
of the effect of HPV vaccination as well as an estimation of 
the proportion of CIN2, CIN3, and cervical cancer that could 
potentially be prevented when women are vaccinated either 
against two (16/18) or seven (16/18/31/33/45/52/58) onco-
genic HPV types.
2 |  MATERIALS AND METHODS
2.1 | Study design
This is a multicountry, cross‐sectional study including four 
countries (Denmark, Norway, Sweden, and Iceland). We 
aimed to collect formalin‐fixed paraffin‐embedded cervical 
histological specimens of 200 cervical cancers and 300 CIN2 
or CIN3, randomly selected from each country, with a smaller 
number of cancers from Iceland due to the limited size of the 
female population. Women with a histologically confirmed di-
agnosis of CIN2, CIN3, or cervical cancer, during 2004‐2006, 
were eligible for the study (2000‐2008 for women with cervi-
cal cancer in Iceland). The study was approved in each coun-
try by the relevant authorities; the Scientific Ethics Committee 
and the Data Protection Board. In total, cervical tissue sam-
ples from 1964 women were collected (Denmark = 502, 
Iceland = 389, Norway = 509, and Sweden = 564). All cer-
vical specimens were classified based on the histological 
diagnosis as CIN2, CIN3 or cervical cancer. Cancers were 
further classified into squamous cell carcinoma (SCC), adeno-
carcinoma (AC), and other/cervical carcinoma not otherwise 
specified (NOS). In total, we excluded 85 specimens, due to 
inadequacy of the sample for HPV testing (n = 64), diagnosis 
other than CIN2, CIN3, or cervical cancer (n = 9), withdrawal 
of consent (n = 5), or lack of appropriate specimen identifica-
tion (n = 7), thereby leaving 1879 samples for study. The age 
distribution of the included women in this study was compa-
rable to the age distribution of all women with cervical high‐
grade lesions and cancer in each country.15,16
2.2 | HPV genotyping
2.2.1 | Sectioning
All formalin‐fixed paraffin‐embedded blocks were sectioned 
according to a standardized protocol (previously verified to 
not result in contaminations) at a commercial, accredited 
laboratory, HistoCenter, Inc in Gothenburg, Sweden. Every 
case‐block was sectioned with a new knife, using new gloves. 
In between each case‐block, a blank‐block containing only 
paraffin was sectioned as a control for contamination. The 
blank‐block was sectioned first. Four 5‐µm sections were 
transferred to a 1.5 mL Eppendorf screw cap tube, using a new 
toothpick. The case‐block was mounted on the microtome 
and six sections, 5 µm each, were made with the same knife 
as the blank‐block. The first and last section were stained 
with hematoxylin‐eosin for rereview by a senior pathologist 
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to assess the histology on the actual tissue, and the four 5‐µm 
sections in‐between were transferred to a tube in the same 
way as the sections from the blank‐block. After each case‐
block, the knife was “removed and the microtome cleaned 
with DNAZap (Applied Biosystems, Waltham, MA, USA).
2.2.2 | DNA extraction, HPV 
genotyping, and Sanger sequencing
All samples, case‐blocks and blank‐blocks, were extracted 
with Xylene as previously described.17 Briefly, 1 mL Xylene 
per sample was incubated in 50°C for 30 minutes followed 
by vortexing and centrifugation 3000 g, for 10 minutes. The 
supernatant was removed with a sterile transfer pipette and 
the process repeated once. After the second removal of xy-
lene, the samples were washed with pure ethanol twice and 
air‐dried. Dried pellets were incubated in 100 µL Digestion 
buffer (50 mmol/L Tris HCl, 1 mmol/L EDTA, pH 8.5) with 
Proteinase K (50 mg/mL) in 37°C for about 24 hours and 
then boiled at 100°C for 10 minutes, to inactivate Proteinase 
K. After extraction, case‐blocks and blank‐blocks were sub-
jected to polymerase chain reaction (PCR) with modified gen-
eral primers (MGP) targeting L1, and HPV genotyped using 
Luminex, as previously described.18,19 Briefly, 44 different 
type‐specific beads were used, 39 for different HPV types, 
three for HPV type variants and two with “universal” probes. 
If a case was HPV negative, both the case‐block and the 
corresponding blank‐block were diluted 1/10 and analyzed 
again. If still HPV negative, a 1/50 dilution was done and the 
analysis repeated again. Case‐blocks and blank‐blocks were 
treated in the same way through the whole process.
Betaglobin real‐time PCR was performed20 on both blank‐
blocks and case‐blocks to detect the absence and presence 
of human DNA. In all analyses, 1 µL extracted material was 
used in all PCRs with a total volume of 25 µL. For a valid 
result, the blank‐block had to be negative in both the beta-
globin and the HPV test and the case‐block had to be positive 
for betaglobin.
For case‐blocks with a valid result positive for a uni-
versal probe, but not for any specific HPV type, the MGP 
PCR product was separated with 2% agarose gel electropho-
resis. Fragments of length 170 bp were cut out and purified 
using QIAquick Gel Extraction Kit (Qiagen, Venlo, The 
Netherlands), 30 µL elution buffer. After purification, the 
product was sent for Sanger sequencing at Eurofins MWG 
Operon, Ebersberg, Germany.
2.3 | Statistical analysis
We assessed the HPV prevalence anddistribution of HPV 
types in the CIN2, CIN3, and cervical cancer specimens. The 
prevalences are shown both among the whole study population 
and among HPV‐positive women. The following HPV types 
were defined as oncogenic: HPV16, 18, 31, 33, 35, 39, 45, 51, 
T A B L E  1  Country‐specific characteristics of the study population (N = 1879)
Total (N = 1879) Denmark (n = 491) Norway (n = 472) Sweden (n = 537) Iceland (n = 379)
n
% 
HPV 
pos. n
% 
HPV 
pos. n
% 
HPV 
pos. n
% 
HPV 
pos. n
% 
HPV 
pos.
Histological diagnosis
CIN (total) 1240 88.7 289 87.2 285 86.7 389 90.8 277 89.5
CIN2a 404 82.7 100 82.0 37 75.7 182 86.3 85 78.8
CIN3b 836 91.6 189 90.0 248 88.3 207 94.7 192 94.3
Cervical cancer (total)c 639 86.4 202 88.6 187 82.4 148 84.5 102 92.2
Squamous cell 
carcinoma
480 89.8 163 92.0 123 86.2 120 85.8 74 97.3
Adenocarcinoma 108 72.2 22 68.2 44 72.7 19 68.4 23 78.3
Other/cervical 
carcinoma
NOS
51 84.3 17 82.4 20 80.0 9 100.0 5 80.0
Age at diagnosis (y) [median (range)]
CIN 31 (19‐88) 31 (20‐78) 34 (19‐88) 31 (19‐83) 30 (19‐75)
Cervical cancer 46 (20‐98) 41 (23‐92) 48 (23‐98) 51 (22‐90) 45 (20‐91)
CIN, cervical intraepithelial neoplasia; HPV pos., human papillomavirus positive; NOS, not otherwise specified.
aP‐value for the difference between countries: P = 0.282. 
bP‐value for the difference between countries: P = 0.036. 
cP‐value for the difference between countries: P = 0.079. 
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T A B L E  2  Distribution of HPV types among women with high‐grade cervical intraepithelial neoplasia (CIN) from four Nordic countries 
(n = 1240)
CIN2 CIN3
n
Among total 
(n = 404)
Among HPV 
pos. (n = 334)
n
Among total 
(n = 836)
Among HPV pos. 
(n = 766)
% % % %
HPV result
Negative 70 17.3 70 8.4
Positive 334 82.7 767 91.6
Oncogenic only 284 70.3 85.0 714 85.4 93.2
Nononcogenic only 21 5.2 6.3 13 1.6 1.7
Oncogenic and 
nononcogenic
29 7.2 8.7 39 4.7 5.1
No. of oncogenic HPV types
1 255 63.1 76.4 622 74.4 81.2
2 40 9.9 12.0 111 13.3 14.5
3‐4 18 4.5 5.4 20 2.4 2.6
Oncogenic HPV typesa
16 145 35.9 43.4 420 50.2 54.8
18 26 6.4 7.8 66 7.9 8.6
31 44 10.9 13.2 101 12.1 13.2
33 28 6.9 8.4 94 11.2 12.3
35 10 2.5 3.0 20 2.4 2.6
39 16 4.0 4.8 12 1.4 1.6
45 10 2.5 3.0 35 4.2 4.6
51 31 7.7 9.3 22 2.6 2.9
52 44 10.9 13.2 67 8.0 8.7
56 13 3.2 3.9 17 2.0 2.2
58 16 4.0 4.8 24 2.9 3.1
59 4 1.0 1.2 20 2.4 2.6
68 2 0.5 0.6 7 0.8 0.9
No. of nononcogenic HPV types
1 47 11.6 14.1 46 5.5 6.0
2‐4 3 0.7 0.9 6 0.7 0.8
Nononcogenic HPV types
6 8 2.0 2.4 7 0.8 0.9
11 6 1.5 1.8 1 0.1 0.1
26 1 0.3 0.3 1 0.1 0.1
42 5 1.2 1.5 4 0.5 0.5
43 0 0.0 0.0 2 0.2 0.3
53 3 0.7 0.9 5 0.6 0.7
66 7 1.7 2.1 7 0.8 0.9
67 7 1.7 2.1 6 0.7 0.8
69 0 0.0 0.0 2 0.2 0.3
70 9 2.2 2.7 14 1.7 1.8
(Continues)
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52, 56, 58, 59, or probably oncogenic: HPV68, HPV types.21 
We assessed the prevalence of HPV16 and/or 18 (HPV16/18), 
HPV31, 33, 45, 52, and/or 58 (HPV31/33/45/52/58), and 
HPV negatives in CIN2, CIN3, and cervical cancer speci-
mens, according to the women’s age at diagnosis. In addition, 
among HPV16/18 positive, HPV31/33/45/52/58 positive and 
HPV‐negative women, we tested for trend in age using logis-
tic regression with women’s age at diagnosis as a continuous 
variable. Age at diagnosis was categorized in 5‐year intervals 
for CIN: ≤24, 25‐29, 30‐34, 35‐39, and ≥40 years, and in 
10‐year intervals for cervical cancer: ≤34, 35‐44, 45‐54, and 
≥55 years. Finally, we estimated the potential preventive ef-
fect for an HPV vaccine protecting against two oncogenic 
types (16/18), and an HPV vaccine protecting against seven 
oncogenic HPV types (16/18/31/33/45/52/58), by adding the 
number of cases caused by these vaccine HPV types alone or 
in combination with other types. We also analyzed the HPV 
prevalence and HPV type distribution by country, but as the 
results for the four countries were similar, only the combined 
data are shown. We compared the HPV prevalence in CIN2, 
CIN3, and cervical cancer between the four countries, and 
in addition, we compared the HPV prevalence between SCC 
and AC by use of the chi‐squared test. All statistical analy-
ses were performed using SAS Software version 9.4 (SAS 
Institute, Cary, NC, USA), with a significance level of 0.05.
3 |  RESULTS
In the present study, we included specimens from 1240 high‐
grade CIN lesions (404 CIN2 and 836 CIN3) and 639 cer-
vical cancer specimens (480 SCC, 108 AC; Table 1). The 
median age at diagnosis of CIN ranged from 30 years in 
Iceland to 34 years in Norway with an overall median age 
of 31 years. The median age at diagnosis for cervical cancer 
ranged from 41 years in Denmark to 51 years in Sweden with 
an overall median age of 46 years among all women. Overall, 
the proportion of specimens that were HPV positive was in 
the range 75.7%‐86.3% for CIN2; 88.3%‐94.7% for CIN3 and 
82.4%‐92.2% for cervical cancer (Table 1). The proportions 
of HPV‐positive cancer specimens from Norway and Sweden 
tended to be lower than for Denmark and Iceland, but the dif-
ference between the four countries did not quite reach statisti-
cal significance (P = 0.079).
Table 2 presents the distribution of HPV types among women 
with high‐grade precancerous cervical lesions for the four 
countries combined. In our study, 82.7% (95% CI 79.0‐86.4) 
of the specimens from women with CIN2 and 91.6% (95% 
CI 89.7‐93.5) of the specimens from women with CIN3 
were HPV positive. A few samples had only nononcogenic 
HPV types (CIN2: 5.2%, 95% CI 3.0‐7.4 and CIN3: 1.6%, 
95% CI 0.7‐2.4). Most CIN2 and CIN3 specimens harbored 
only a single type of oncogenic HPV: CIN2: 63.1% (95% CI 
58.4‐67.8) and CIN3: 74.4% (95% CI 71.4‐77.4). The most 
prevalent HPV type was HPV16 in CIN2 (35.9%, 95% CI 
31.2‐40.6 among all and 43.4%, 95% CI 38.1‐48.8 among 
HPV positive) and CIN3 (50.2%, 95% CI 46.8‐53.6 among 
all and 54.8%, 95% CI 51.3‐58.4 among HPV positive). The 
next most common type was HPV31 (CIN2: 10.9%, 95% 
CI 7.8‐13.9 among all and CIN3: 12.1%, 95% CI 9.9‐14.3 
among all), followed by (in decreasing order) HPV52, 51 and 
33 among women with CIN2 and HPV33, 52, and 18 among 
women with CIN3. HPV70 was the most prevalent nononco-
genic HPV type both in CIN2 and in CIN3.
The distribution of HPV types among women with cervi-
cal cancer is displayed in Table 3. Overall, HPV was detected 
in 86.4% (95% CI 83.7‐89.1) of cervical cancer. The HPV de-
tection rate was higher in SCC (89.8%, 95% CI 87.1‐92.5) than 
in AC (72.2%, 95% CI 63.6‐80.8; P < 0.0001). Infection with 
single HPV types was the commonest among cervical cancer 
overall (80.9%, 95% CI 77.9‐84.0), both in SCC (83.1%, 95% 
CI 79.8‐86.5) and AC (72.2%, 95% CI 63.6‐80.8). HPV16 
and HPV18 were the most frequent HPV types in cervical 
cancer overall (48.8%, 95% CI 44.9‐52.7 and 15.3%, 95% 
CI 12.5‐18.1, respectively). Among all SCC specimens, 
the prevalence of HPV16 was 53.3% (95% CI 48.9‐57.8), 
CIN2 CIN3
n
Among total 
(n = 404)
Among HPV 
pos. (n = 334)
n
Among total 
(n = 836)
Among HPV pos. 
(n = 766)
% % % %
73 2 0.5 0.6 1 0.1 0.1
81 1 0.3 0.3 4 0.5 0.5
89 3 0.7 0.9 3 0.4 0.4
91 1 0.3 0.3 1 0.1 0.1
HPV pos., human papillomavirus positive.
aThe sum of specific oncogenic HPV types exceeds the total number of HPV positive due to multiple infections. 
T A B L E  2  (Continued)
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T A B L E  3  Distribution of HPV types among women with cervical cancer from four Nordic countries (n = 639)
Cervical cancer (total)a Squamous cell carcinoma Adenocarcinoma
n
Among 
total 
(n = 639)
Among HPV 
pos. (n = 552)
n
Among 
total 
(n = 480)
Among HPV 
pos. (n = 431)
n
Among 
total 
(n = 108)
Among HPV 
pos. (n = 78)
% % % % % %
HPV result
Negative 87 13.6 49 10.2 30 27.8
Positiveb 552 86.4 431 89.8 78 72.2
Oncogenic 
only
535 83.7 96.9 416 86.7 96.5 76 70.4 97.4
Nononcogenic 
only
11 1.7 2.0 11 2.3 2.6 0 0.0 0.0
Oncogenic and 
nononcogenic
6 0.9 1.1 4 0.8 0.9 2 1.9 2.6
No. of oncogenic HPV types
1 517 80.9 93.7 399 83.1 92.6 78 72.2 100.0
2‐3 24 3.8 4.4 21 4.4 4.8 0 0.0 0.0
Oncogenic HPV typesc
16 312 48.8 56.5 256 53.3 59.4 39 36.1 50.0
18 98 15.3 17.8 47 9.8 10.9 33 30.6 42.3
31 21 3.3 3.8 21 4.4 4.9 0 0.0 0.0
33 35 5.5 6.3 33 6.9 7.7 1 0.9 1.3
35 10 1.6 1.8 8 1.7 1.9 0 0.0 0.0
39 15 2.4 2.7 15 3.1 3.5 0 0.0 0.0
45 41 6.4 7.4 31 6.5 7.2 5 4.6 6.4
51 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
52 10 1.6 1.8 9 1.9 2.1 0 0.0 0.0
56 6 0.9 1.1 5 1.0 1.2 0 0.0 0.0
58 4 0.6 0.7 4 0.8 0.9 0 0.0 0.0
59 14 2.2 2.5 13 2.7 3.0 0 0.0 0.0
68 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
No. of nononcogenic HPV types
1 17 2.7 3.1 15 3.1 3.5 2 1.9 2.6
Nononcogenic HPV types
6 3 0.5 0.5 2 0.4 0.5 1 0.9 1.3
11 1 0.2 0.2 1 0.2 0.2 0 0.0 0.0
26 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
42 1 0.2 0.2 1 0.2 0.2 0 0.0 0.0
43 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
53 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
66 3 0.5 0.5 3 0.6 0.7 0 0.0 0.0
67 3 0.5 0.5 2 0.4 0.5 1 0.9 1.3
69 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
(Continues)
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followed by HPV18 (9.8%, 95% CI 7.1‐12.5), HPV33, 45, 
and 31. HPV16 was also the most prevalent HPV type among 
all AC specimens (36.1%, 95% CI 26.9‐45.3), while HPV18 
accounted for almost all the remaining infections within this 
group (30.6%, 95% CI 21.7‐39.4). The prevalence of nonon-
cogenic HPV types was very low in cervical cancer, ranging 
from 0% to 0.6%.
Figure 1 shows the proportion of specimens that were 
HPV16/18 positive, HPV31/33/45/52/58 positive or HPV 
negative in relation to the women’s age at diagnosis. Among 
women with CIN2 and CIN3, the prevalence of HPV16/18 
decreased with increasing age at diagnosis (P < 0.0001 for 
both). In contrast, the prevalence of HPV31/33/45/52/58 re-
mained relatively constant in all age groups, and the preva-
lence of HPV‐negative samples increased with increasing age 
(P < 0.0001 for both). Among the women with SCC and AC, 
the prevalence of HPV16/18 decreased with increasing age 
at diagnosis (P < 0.0001 for both), whereas the prevalence 
of HPV31/33/45/52/58 increased slightly with increasing age 
among women with SSC (P = 0.055). The age pattern in the 
prevalence of HPV‐negative samples showed an increase with 
increasing age at diagnosis (SCC: P = 0.0003; AC: P < 0.0001).
Figure 2 shows the potential preventive effect of HPV vac-
cines protecting against two oncogenic HPV types (16/18) 
or seven oncogenic HPV types (16/18/31/33/45/52/58). In 
total, 42% (95% CI 37.0‐46.7), 57% (95% CI 53.8‐60.5), 
and 64% (95% CI 60.3‐67.7) of CIN2, CIN3, and cervical 
cancer, respectively, could be prevented, if women were 
vaccinated with an HPV vaccine preventing two oncogenic 
HPV types (16/18), assuming that HPV16/18 caused the 
lesion, if present (corresponding estimates among HPV 
positive: CIN2: 51%, 95% CI 45.2‐56.0, CIN3: 62%, 
95% CI 59.0‐65.8, and cervical cancer: 74%, 95% CI 
70.4‐77.8). Lesions positive for HPV16/18, but no other 
oncogenic HPV, accounted for 33% (95% CI 28.3‐37.5), 
47% (95% CI 43.4‐50.2), and 62% (95% CI 58.4‐65.9) 
of CIN2, CIN3, and cervical cancer, respectively (corre-
sponding estimates among HPV positive: CIN2: 40%, 95% 
CI 34.5‐45.1, CIN3: 51%, 95% CI 47.5‐54.6 and cervical 
cancer: 72%, 95% CI 68.2‐75.7). The preventive potential 
increased to 68% (95% CI 63.0‐72.2) for CIN2, 85% (95% 
CI 82.4‐87.2) for CIN3, and 80% (95% CI 77.0‐83.2) for 
cervical cancer if five additional oncogenic HPV types 
(31/33/45/52/58) were included in the vaccine (corre-
sponding estimates among HPV positive: CIN2: 82%, 95% 
CI 77.6‐85.9, CIN3: 93%, 95% CI 90.7‐94.4 and cervical 
cancer: 93%, 95% CI 90.6‐94.9).
4 |  DISCUSSION
In this large multicountry study on cervical specimens ob-
tained in the period 2004‐2006 from almost 2000 women 
with high‐grade precancerous cervical lesions or cervical 
cancer, we found that HPV16 and 31 were the most com-
mon types in CIN2 and CIN3, while HPV16 and 18 were the 
most common types in cervical cancer, with HPV18 being 
far more common in AC than in SCC. In CIN2 and CIN3 as 
well as cancer specimens, the prevalence of HPV‐negative 
samples increased with increasing age at diagnosis, while 
the prevalence of HPV types 16/18 was found to decrease. 
The preventive potential of HPV16/18 vaccination was 57% 
and 64% in CIN3 and cervical cancer, respectively, while 
inclusion of HPV31/33/45/52/58 in a vaccine increased the 
protection to more than 80% in both the groups.
Other studies also report HPV16 as the most prevalent type 
in women with CIN2, CIN3, and cervical cancer, followed by 
HPV31 in CIN2 and CIN3 and HPV18 in cancer.4,22,23 The 
majority of the oncogenic HPV types detected in our study 
were present as single type HPV infections, ranging from 
Cervical cancer (total)a Squamous cell carcinoma Adenocarcinoma
n
Among 
total 
(n = 639)
Among HPV 
pos. (n = 552)
n
Among 
total 
(n = 480)
Among HPV 
pos. (n = 431)
n
Among 
total 
(n = 108)
Among HPV 
pos. (n = 78)
% % % % % %
70 4 0.6 0.7 4 0.8 0.9 0 0.0 0.0
73 1 0.2 0.2 1 0.2 0.2 0 0.0 0.0
81 1 0.2 0.2 1 0.2 0.2 0 0.0 0.0
89 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
91 0 0.0 0.0 0 0.0 0.0 0 0.0 0.0
HPV pos., human papillomavirus positive.
aCervical cancer (total) includes squamous cell carcinoma, adenocarcinoma, and other/cervical carcinoma not otherwise specified. 
bP‐value for the difference between SCC and AC: P < 0.0001. 
cThe sum of specific oncogenic HPV types exceeds the total number of HPV positive due to multiple infections. 
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around 63% in CIN2 to 81% in cervical cancer. In the rela-
tively few samples with multiple infections, it can be difficult 
to determine which type caused the lesion.24 Our findings 
comparing AC and SCC also confirm that the contribution of 
HPV18 is substantially higher in AC than in SCC.4
With increasing age at diagnosis of the women, the spec-
imens were less likely to harbor HPV16/18. A decrease in 
the prevalence of HPV16/18 with respect to woman’s age 
at diagnosis has been reported in previous studies.13,14,25 
HPV16 possesses a unique carcinogenic potential com-
pared to other HPV types, and has a higher probability of 
persistence, and an overall increasing prevalence with in-
creasing severity of the cervical lesion.26,27 The transition 
from normal epithelium to CIN and cervical cancer appears 
to be faster in HPV16/18‐positive women than in women 
positive for other HPV types, which correlates well with 
reports of a lower mean age at diagnosis in women with 
HPV16/18‐positive CIN and cervical cancer compared 
to those positive for non‐HPV16/18 HPV types.11,28,29 
Furthermore, CIN lesions with HPV16 infection found in 
screening programs may be larger and easier for colpos-
copists to identify and remove compared with non‐HPV16 
positive lesions, which could lead to a lower prevalence of 
HPV16‐related cancers among older women.30 Finally, our 
results may in theory be explained by a cohort effect. In 
contrast, the prevalence of HPV31/33/45/52/58 displayed a 
more stable prevalence across age groups, which is also in 
line with previous findings.5
Infection with HPV is recognized as a necessary cause of 
cervical cancer, so our finding of around 10% HPV‐negative 
specimens in women with cervical cancer is relatively high, 
although consistent with several other studies.5,12,13,22 We 
present the distribution of HPV types among the whole study 
population, and among HPV‐positive women. In our study, 
the cancer specimens from Norway and Sweden had a higher 
proportion of HPV negative than the cancer samples from 
Denmark and Iceland, although this difference was not sta-
tistically significant. The median age at diagnosis also tended 
to be higher in women with cervical cancer from Norway and 
Sweden than from Denmark and Iceland. HPV negativity 
can be due to technical limitations, limited quality of biopsy 
specimens31 or integration of HPV into the host genome caus-
ing loss of the L1 sequences otherwise targeted by the MGP 
primer.32 Despite the wide range of HPV types tested for in 
this study, theoretically some of the HPV‐negative samples 
may be infected with other HPV types not detectable by this 
PCR method. As also reported by others,25,32 women with 
AC were more likely to be tested HPV negative (27.8%) than 
women with SCC (10.2%). This finding may be associated 
with non‐HPV‐related endometrial cancer in the lower part of 
the uterine body being misclassified as cervical AC.33 Finally, 
a recent European multicenter study found extensive variation 
F I G U R E  1  Prevalence of HPV16/18 positive (A), HPV31/33/45/52/58 positive (B) and HPV negative (C) in relation to woman’s age at 
diagnosis among Nordic women with CIN2, CIN3, squamous cell carcinoma or adenocarcinoma. AC, adenocarcinoma; CIN, cervical intraepithelial 
neoplasia; HPV, human papillomavirus; SCC, squamous cell carcinoma
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in the HPV prevalence (0%‐90%) among different histological 
subgroups of cervical AC, suggesting that a fraction of AC 
may actually not be HPV related.29 In our study, the number of 
AC samples was limited and AC subgroups were not assessed.
A small number of CIN3 and cervical cancer cases har-
bored nononcogenic HPV types only, as reported in other 
studies.4,32 This finding is likely due to coinfection with an 
undetected oncogenic HPV type.
Since the introduction of HPV vaccination programs, eco-
logical studies have reported declines of genital warts and CIN 
of different grades.7,34 Similar results have been found by re-
cent nationwide cohort studies with information on individual 
HPV vaccination status. A Danish study compared women 
vaccinated with at least one dose of an HPV16/18 vaccine with 
unvaccinated women and reported a 73% reduction in risk of 
CIN2/3, and 80% of CIN3 alone, for the youngest birth cohort 
(born 1993‐1994), which also had the highest HPV vaccina-
tion coverage.9 A similar study among Swedish women found 
a 75% reduction in risk of CIN2+, and 84% of CIN3+, when 
comparing fully vaccinated (three doses of an HPV16/18 vac-
cine, vaccination initiated before age 17) women with unvac-
cinated women.8 Kjaer et al10 reported HPV results from more 
than 40 000 Danish women in a pre‐HPV vaccination period 
and found a potential preventive effect of HPV16/18 vacci-
nation of 74% in cervical cancer (CIN2: 37%; CIN3: 66%), 
while an HPV vaccine targeting seven oncogenic HPV types 
(HPV16/18/31/33/45/52/58) was predicted to prevent 89% of 
cervical cancer (CIN2: 80%; CIN3: 91%). These estimated 
preventive effects are slightly greater than the effects found 
among the study population in the present study, but similar to 
our results among HPV‐positive women and may therefore be 
explained by the generally higher prevalence of HPV‐positive 
samples in all histological categories in Kjær et al10 than in the 
present study. It should be noted that the HPV testing in that 
study was done on cytology samples, whereas in the present 
study HPV testing was performed on histological specimens.
In the present study, we found a substantial effect of in-
cluding five additional oncogenic HPV types compared to an 
F I G U R E  2  Estimated potential 
preventive effect of HPV 16/18 vaccine (A) 
and HPV 16/18/31/33/45/52/58 vaccine (B) 
among Nordic women with CIN2, CIN3 and 
cervical cancer. CIN, cervical intraepithelial 
neoplasia; HPV, human papillomavirus
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HPV16/18 vaccine among women with high‐grade precancer-
ous cervical lesions, where the potential prevention increased 
from 42% to 68% in CIN2 and from 57% to 85% in CIN3. This 
illustrates the high prevalence of especially HPV31, 33, and 
52 in CIN2 and CIN3. Furthermore, this underlines the poten-
tial impact of a vaccine including HPV16/18/31/33/45/52/58 
or a vaccine with substantial cross‐protection against these 
types on the future incidence of high‐grade CIN among 
Nordic women. When comparing the effect of an HPV16/18 
vaccine to an HPV16/18/31/33/45/52/58 vaccine on cervical 
cancer, the estimated prevention increased from 64% to 80% 
(among HPV positive: 74%‐93%), corresponding to results 
from a recent population‐based US study and a meta‐anal-
ysis of two worldwide HPV distribution studies.5,31 Based 
on recent incidence data on cervical cancer from the Nordic 
region, around 1200 women are at present diagnosed with 
cervical cancer in Denmark, Iceland, Norway, and Sweden 
combined every year.16 Implementation of an HPV16/18 vac-
cine would prevent approximately 750 cervical cancers per 
year, while the use of an HPV16/18/31/33/45/52/58 vaccine 
would increase this estimated preventive effect to around 940 
cervical cancers. Moreover, since all of the oncogenic HPV 
types we detected in the AC specimens are included in the 
HPV16/18/31/33/45/52/58 vaccine, we estimate a potential 
100% reduction in HPV‐positive AC, under the assumption 
of full vaccination coverage and long‐term effectiveness.
Strengths of our study include the population‐based de-
sign, the large sample size, and inclusion of women from 
four Nordic countries with a similar demographic compo-
sition, thus making our results generalizable to the Nordic 
female population. Our HPV results were from histologically 
confirmed diagnostic categories (CIN2, CIN3, and cervical 
cancer), which increases the likelihood of a true causal asso-
ciation. HPV genotyping was performed by use of a highly 
sensitive PCR method at a central reference laboratory to en-
sure standardized testing. In addition, we tested for a wide 
spectrum of HPV types. Previous studies have reported re-
sults for CIN or cervical cancer overall, or in some cases for 
combined CIN2+ or CIN3+ groups, whereas we provide 
results for CIN2 and CIN3 separately, as well as histologi-
cal subgroups (SCC, AC) of cervical cancer, to fully report 
the differences in specific genotypes between groups.32,35 
Furthermore, we show age‐stratified results of HPV16/18 and 
HPV31/33/45/52/58 prevalence, which is important because 
the HPV16/18 prevalence has been shown to differ between 
age groups.23,28,32 Our study also has limitations. Despite the 
high sensitivity of the PCR method, some HPV infections 
may have not been detected. On the other hand, very sensitive 
HPV testing may detect latent or transient HPV infections, 
which are not necessarily causal.
In conclusion, we present here a baseline assessment 
of the overall and type‐specific HPV prevalence and age‐
specific distribution in both CIN2 and CIN3 as well as 
cervical cancer among women from four Nordic countries 
before implementation of HPV vaccination. These re-
sults form the basis for future monitoring of the effect of 
HPV vaccination. In addition, they contribute with esti-
mates of the potential preventive impact of both HPV16/18 
and HPV16/18/31/33/45/52/58 vaccination in the Nordic 
countries.
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